Effects of different administration times of tablets with a combination of telmisartan and amlodipine on CKD patients with hypertension

Effects of different administration times of tablets with a combination of telmisartan and amlodipine on CKD patients with hypertension - Effects of tablets with a combination of telmisartan and amlodipine on CKD patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011531

Enrollment

Registered

2013-10-01

Start date

2013-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CKD with hypertension

Interventions

Morning administration of tablets with a combination of telmisartan and amlodipine Evening administration of tablets with a combination of telmisartan and amlodipine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients whose hypertension not well-controlled 2)Patients with CKD stage G2 to G3

Exclusion criteria

Exclusion criteria: 1)Patients allergic to CCB or ARB 2)Patients with liver dysfunction 3)Patients with pregnancy, or with its possibility

Design outcomes

Primary

Measure	Time frame
serum creatinine, blood urea nitrogen, estimated GFR, proteinuria	—

Countries

Japan

Contacts

Public ContactHirokazu Okada

Saitama Medical University Department of Nephrology

hirookda@saitama-med.ac.jp049-276-1611

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026